RCHOP and venetoclax should be effective in high-grade lymphomas that express BCL2 protein, are not class B, and co-depend on BCL2 and MCL1 (53% of our diagnostic DLBCL samples). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.